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Alzheimer’s disease (AD) is a clinically heterogeneous
disease that may have atypical presentations with focal
cortical syndromes and relatively preserved episodic
memory. The posterior variant of AD has two subtypes:
occipitotemporal, presenting with visuoperceptive
impairment, and biparietal, presenting with visuospatial
dysfunction and apraxia. We report a case of a 51-year-
old woman with progressive limb apraxia and choreiform
movements. Her neuropsychological evaluation was
compatible with dementia, and revealed ideomotor and
ideational limb apraxia, severe visuoconstructive ability
impairment, dyscalculia and posterior aphasia. Workup
excluded metabolic, infectious, inﬂammatory or
neoplastic causes, and hereditary conditions as
Huntington’s disease and familial AD. Cerebrospinal ﬂuid
biomarkers revealed β-amyloid reduction and τ protein
increase. Brain imaging showed marked biparietal
atrophy and hypoperfusion, and widespread cortical
β-amyloid deposition. Biparietal variant of AD was
diagnosed and acetylcholinesterase inhibitor treatment
induced clinical stabilisation. AD may present with
atypical features and a high clinical suspicion is
necessary for an early diagnosis.
BACKGROUND
According to the original criteria,1 Alzheimer’s
disease (AD) was assumed to be a clinically homoge-
neous disease, with memory impairment being the
initial and dominant feature.2–5 Nonetheless, atyp-
ical clinical presentations, mainly with aphasic and
frontal-executive proﬁles, have been frequently
described in patients with pathologically conﬁrmed
diagnosis of AD.6–8 In 2011, the new criteria from
the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for
AD proposed three non-amnestic presentations: lan-
guage and visuospatial presentations, and frontal
dysfunction.9 Recently, the International Working
Group published the IWG-2 criteria10 and proposed
speciﬁc diagnostic criteria for the atypical forms of
AD, including a posterior, logopenic and frontal
variant. These AD variants usually present as focal
cortical syndromes with predominant impairment
of cognitive functions other than episodic memory,
such as visual perception, visuospatial functions,
language or frontal functions.5–8 11–13
We report the case of a 51-year-old woman pre-
senting with limb apraxia, posterior aphasia,
impairment of visuospatial functions and chorei-
form limb movements associated with marked
biparietal atrophy and hypoperfusion on
neuroimaging, investigation of which ultimately
allowed the diagnosis of a rare atypical presentation
of AD, the biparietal variant of AD.
CASE PRESENTATION
A 51-year-old right-handed housewife with 4 years
of formal education reported progressive difﬁculty
with object manipulation leading to a compromise
of manual tasks. During the next 2 years she also
developed involuntary movements of the limbs and
gradually lost the ability to write and perform daily
household activities.
Her medical history was unremarkable and she had
no family history of dementia. There was a history of
alcohol abuse in multiple elements of the family,
including her father, brother, uncle and cousin, and a
history of suicide in her brother and uncle.
The neurological examination revealed severe
bilateral ideomotor apraxia and choreiform move-
ments of the limbs, both more pronounced in the
distal left upper extremity; hyperactive tendon
reﬂexes and positive glabellar; and snout and pal-
momental reﬂexes. The patient’s brief cognitive
status was compatible with dementia, with a score
of 21/30 on the Mini-Mental State Examination
(MMSE), a score of 14/30 on the Montreal
Cognitive Assessment and a score of 21/60 on the
Alzheimer’s Disease Assessment Scale-Cognitive.
INVESTIGATIONS
A comprehensive neuropsychological assessment
identiﬁed ideomotor and ideational apraxia, severe
impairment of visuoconstructive ability (ﬁgure 1),
agraphia, dyscalculia and posterior aphasia (with
anomia, semantic paraphasias and impaired com-
prehension of complex verbal information). Frontal
functions such as Luria sequences, verbal initiative,
graph-motor ﬂexibility and abstract reasoning were
moderately compromised. A mild impairment of
visual and verbal episodic memory was also identi-
ﬁed, but her orientation to time, space and person
was preserved.
Blood workup, including complete blood count,
coagulation study, biochemistry, erythrocyte sedi-
mentation rate, C reactive protein, protein electro-
phoresis, folic acid, cyanocobalamin, thyroid
function tests, serological testing (Treponema
pallidum, Borrelia burgdorferi and Brucella) and
progranulin measurement were unremarkable, as
were cerebrospinal ﬂuid (CSF) cytochemical ana-
lysis, direct microscopy and cultures. CSF biomar-
kers study showed a marked reduction of β-amyloid
(Aβ) protein levels (122.7 pg/mL; normal values
>500 pg/mL), very high titres of τ protein
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(1106.8 pg/mL; normal values 119.4±30.4 pg/mL) and border-
line levels of phosphorylated τ protein (61 pg/mL; normal values
<61 pg/mL).
Brain MRI revealed marked bilateral parietal atrophy and
moderate bilateral frontal, temporal and occipital atrophy, with
relative preservation of hippocampal volumes (ﬁgure 2). Brain
single photon emission CT (SPECT) imaging revealed severe
hypoperfusion in the parietal lobes and mild bilateral frontal
and temporal hypoperfusion (ﬁgure 3). Positron emission tom-
ography with 11C-Pittsburgh compound B positron emission
tomography (PiB-PET) revealed marked and diffuse increase in
Aβ deposition in cerebral cortex and caudate nuclei (ﬁgure 4).
Apolipoprotein E (ApoE) genotyping revealed ε3/ε3 genotype.
Genetic testing was negative for mutation analysis for
Huntington’s disease, Huntington’s disease-like (HDL)-1 and
HDL-2, dentatorubropallidoluysian atrophy (DPRLA), spinocere-
bellar ataxia 17 (SCA17), neuroferritinopathy and AD, including
presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor
protein (APP) mutations.
TREATMENT, OUTCOME AND FOLLOW-UP
Treatment with an acetylcholinesterase inhibitor (donepezil,
10 mg/day) induced clinical stabilisation and the patient pre-
sented a MMSE score of 20/30 after 2 years of treatment.
DISCUSSION
Atypical presentations of AD are estimated to occur in 6–14%
of cases and usually start at an earlier age than typical AD, pre-
senting with predominant focal cortical deﬁcits other than epi-
sodic memory, which is usually relatively well preserved until
late in the course of the disease.5–8 11–14 In these atypical forms,
the neuropsychological proﬁle and neuroimaging ﬁndings have
been found to reﬂect the clinical syndrome and to correlate
with the distribution of AD pathology, suggesting that the
Figure 1 Patient copies of ﬁgures
revealing constructional apraxia.
Figure 2 Brain MRI showing marked atrophy of both parietal lobes and moderate atrophy of the frontal, temporal and occipital lobes.
Hippocampal volumes are relatively preserved.
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distribution of the pathology is more a determinant than the
nature of the disease in deﬁning the clinical syndrome.5 15 The
reason for this disparity in regional neuronal vulnerability in
AD variants remains unsolved, although biological and patho-
logical footprints related to a genetic propensity are discussed.16
The posterior variant of AD presents as posterior cortical
atrophy and is proposed to be divided into two subtypes,6 10
reﬂecting the predominant site of AD pathology: the occipito-
temporal variant, which results from disruption of the ventral
visual pathway, responsible for visual recognition (Ventral
stream—WHAT), and presents with early, predominant and pro-
gressive visuoperceptual impairment or visual agnosia with
impairment in identifying objects, symbols, words and faces;
and the biparietal variant, which results from disruption of the
occipitoparietal stream of the visual pathway responsible for
visuospatial and perceptual motor processing (Dorsal stream—
WHERE), crucial in object location, visual guidance of move-
ments and motor planning, and presents with early, predomin-
ant and progressive visuospatial dysfunction, featured by Balint
or Gerstmann syndromes, limb apraxia or neglect, with pre-
served basic visual abilities.5 6 17
The biparietal variant of AD was ﬁrst denominated as progres-
sive biparietal atrophy and was reported to be associated with
marked bilateral parietal lobe atrophy and hypoperfusion in neu-
roimaging, and with predominant and severe parietal lobe involve-
ment by AD pathology in neuropathological examination.5 6 15
Our patient’s clinical presentation with limb apraxia, agra-
phia, posterior aphasia and impairment of visuospatial func-
tions, reﬂect parietal dysfunction and can be included in the
biparietal variant of AD. The observed exuberant choreiform
limb movements can be explained as resulting from loss of
multimodal sensory inputs to the parietal lobe with subsequent
interruption of the normal coordination of motor output.18 19
In fact, focal motor symptoms, including limb clumsiness,
apraxia, ataxia, hemiparesis, dystonic posturing, myoclonus,
athetosis, choreoathetosis, pseudoathetosis and pseudocor-
eoathetosis, or posterior alien hand syndrome, have been docu-
mented in several reports of patients with parietal lobe
damage.18 20–27 Besides, the alternative diagnosis of
Huntington’s disease or HDL, supported by a family history of
addiction and suicide, was excluded by genetic study. Other
medical conditions that may account for the clinical symptoms
such as severe depression, cerebrovascular disease and toxic,
inﬂammatory or metabolic disorders, were also excluded.
The IWG-2 proposed criteria for atypical AD diagnosis10
include a clinical phenotype consistent with the known atypical
presentations (posterior, logopenic and frontal variants) and at
least one in vivo evidence of Alzheimer’s pathology: CSF biomar-
kers with decreased levels of Aβ protein together with elevated
levels of total τ or phosphorylated τ proteins; increased tracer
retention on amyloid PET (PiB-PET); or the presence of an auto-
somal dominant mutation of AD. Our patient presented a CSF
Figure 3 Brain single photon emission CT scan showing severe hypoperfusion of both parietal lobes, more marked on the right, and mild
hypoperfusion of frontal and temporal lobes.
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proﬁle typical of AD, with marked reduction of Aβ protein levels
and very high titres of τ protein, and also a positive biomarker
for Aβ cortical deposition. Although some authors report greater
11C-PiB uptake in the posterior cortex of patients with posterior
cortical atrophy,28–31 the majority of reports found no correl-
ation between Aβ deposits and the clinical syndrome or the
regional brain dysfunction, and most cases present with wide-
spread 11C-PiB uptake, as in the case of our patient.32–37
The presence of atrophy in MRI and hypoperfusion in ﬂuoro-
deoxyglucose (FDG)-PET are no longer considered useful
markers for AD diagnosis, as they lack pathological speciﬁcity,
and are now considered markers of regional structural and meta-
bolic changes, probably useful to monitor disease progression.10
In the case of our patient, the MRI revealed marked bilateral
parietal atrophy with relative preservation of hippocampal
volumes as well as severe hypoperfusion in the parietal lobes in
SPECT. The genetic study was negative for the most common AD
mutations (PSEN1, PSEN2 or APP), which is acceptable as the
patient had no family history of dementia, and the familial auto-
somal dominant forms of AD usually have an earlier onset and
are very rare, being estimated to account for less than 5% of AD
cases.38 ApoE genotyping revealed a common non-risk ε3/ε3
genotype, a result also comprehensible as APOE4, which is gen-
erally considered a risk factor for late-onset forms of AD.39
The presence of CSF biomarkers as well as a positive amyloid
tracer on PET, surrogate markers of Alzheimer’s pathology,
allowed the diagnosis of AD in our patient, which is reinforced
by the clinical stabilisation induced by an acetylcholinesterase
inhibitor. Moreover, the main clinical features and also the
imaging changes support the subclassiﬁcation as biparietal
variant, one of the atypical focal forms of AD described in the
most recent criteria. According to these criteria, further work is
needed in order to better characterise the clinical core of the
atypical presentations using the same conceptual paradigms
implemented for the amnestic typical AD.10
Figure 4 Pittsburgh compound B
(PiB) positron emission tomography
showing increased β-amyloid
deposition in cerebral cortex with high
11C-PiB uptake in the posterior
cingulated gyrus, precuneus and in the
frontal, parietal, lateral temporal and
occipital lobes. Increased 11C-PiB
uptake is also seen in caudate nuclei.
Learning points
▸ Alzheimer’s disease (AD) is a clinically heterogeneous
disease that may have atypical presentations.
▸ Atypical AD usually presents earlier than typical cases and
episodic memory is relatively preserved.
▸ The main atypical AD phenotypes are the posterior variant,
logopenic variant and frontal variant.
▸ The posterior variant of AD has two main subtypes: the
occipitotemporal variant, which presents with visuoperceptive
impairment, and the biparietal variant, which usually
presents with visuospatial dysfunction and apraxia.
▸ According to the recently proposed criteria, further work is
needed in order to better characterise the clinical core of
these atypical presentations, using the same conceptual
paradigms implemented for the amnestic typical AD.
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